US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Arin Tactical Tail Risk ETF

91.06

-0.0647-0.07%

Volume:2.49K

Turnover:226.82K

Market Cap:89.16M

PE:- -

High:91.08

Open:91.08

Low:91.01

Close:91.12

52wk High:91.21

52wk Low:45.10

Shares:979.15K

Float Shares:959.15K

Volume Ratio:3.69

T/O Rate:0.26%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Intellia’s NTLA-2001 Hits Key Milestone in ATTR Gene-Editing Trial, Raising the Stakes in Amyloidosis

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN

Intellia Therapeutics (NTLA) Is Up 20.7% After FDA Halts MAGNITUDE ATTR-CM Trial Over Safety Event - Has The Bull Case Changed?

Simply Wall St.

Bayer’s New Phase 4 ATTR-CM Study Tests Switching From Tafamidis to Acoramidis

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ATTR"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ATTR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATTR\",,,,,undefined,":{"symbol":"ATTR","market":"US","secType":"STK","nameCN":"Arin Tactical Tail Risk ETF","latestPrice":91.055,"timestamp":1770238800000,"preClose":91.1197,"halted":0,"volume":2492,"delay":0,"changeRate":-0.0007100550155453516,"floatShares":959146,"shares":979146,"eps":0,"marketStatus":"Post-Mkt","change":-0.0647,"latestTime":"02-04 17:13:31 EST","open":91.08,"high":91.08,"low":91.01,"amount":226820.05,"amplitude":0.000768,"askPrice":136.56,"askSize":200,"bidPrice":77.74,"bidSize":100,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770253200000},"marketStatusCode":4,"adr":0,"exchange":"CBOE","adjPreClose":91.1197,"sharesOutstanding":979146,"nav":91.22,"aum":89317698.12,"bidAskSpread":0,"volumeRatio":3.690758},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATTR\",,,,,undefined,":{"symbol":"ATTR","floatShares":959146,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":3.690758,"shares":979146,"dividePrice":0,"high":91.08,"amplitude":0.000768,"preClose":91.1197,"low":91.01,"week52Low":45.1,"pbRate":"--","week52High":91.21,"institutionHeld":0,"latestPrice":91.055,"committee":-0.333333,"eps":0,"divideRate":0,"volume":2492,"delay":0,"ttmEps":0,"open":91.08,"prevYearClose":90.4492,"prevWeekClose":91.0958,"prevMonthClose":91.0958,"prevQuarterClose":90.4492,"fiveDayClose":91.1271,"twentyDayClose":90.6853,"sixtyDayClose":90.085},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATTR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATTR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ATTR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATTR\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2607104040","title":"Intellia’s NTLA-2001 Hits Key Milestone in ATTR Gene-Editing Trial, Raising the Stakes in Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2607104040","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607104040?lang=en_us&edition=fundamental","pubTime":"2026-01-31 00:31","pubTimestamp":1769790694,"startTime":"0","endTime":"0","summary":"Intellia Therapeutics Inc ($NTLA) announced an update on their ongoing clinical study. Study Overview – Intellia Therapeutics is running a Phase 1 ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/intellias-ntla-2001-hits-key-milestone-in-attr-gene-editing-trial-raising-the-stakes-in-amyloidosis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/intellias-ntla-2001-hits-key-milestone-in-attr-gene-editing-trial-raising-the-stakes-in-amyloidosis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861558580.USD","BK4588","ATTR","LU1861559042.SGD","BK4556","BK4585","BK4139","NTLA","BK4535"],"gpt_icon":0},{"id":"2606782835","title":"Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN","url":"https://stock-news.laohu8.com/highlight/detail?id=2606782835","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606782835?lang=en_us&edition=fundamental","pubTime":"2026-01-27 21:00","pubTimestamp":1769518800,"startTime":"0","endTime":"0","summary":"Plan to resume MAGNITUDE-2 patient enrollment and dosing FDA engagement ongoing regarding clinical hold on MAGNITUDE Phase 3 clinical trial in ATTR-CM CAMBRIDGE, Mass., Jan.  27, 2026  (GLOBE NEWSWIRE","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/27/3226448/0/en/Intellia-Therapeutics-Announces-FDA-Lift-of-Clinical-Hold-on-MAGNITUDE-2-Phase-3-Clinical-Trial-in-ATTRv-PN.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ATTR","NTLA","BK4535","IE0009354923.USD","LU1861558580.USD","BK4183","BK4139","BK4556","IND","ODD","BK4585","BK4588","LU1861559042.SGD"],"gpt_icon":0},{"id":"2603628923","title":"Intellia Therapeutics (NTLA) Is Up 20.7% After FDA Halts MAGNITUDE ATTR-CM Trial Over Safety Event - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2603628923","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603628923?lang=en_us&edition=fundamental","pubTime":"2026-01-15 04:26","pubTimestamp":1768422396,"startTime":"0","endTime":"0","summary":"In early January 2026, Intellia Therapeutics reported a fatal safety event and Grade 4 liver abnormalities in its Phase 3 MAGNITUDE ATTR-CM trial, prompting the FDA to place both MAGNITUDE and MAGNITUDE-2 studies on clinical hold while the company works with regulators on a path forward for nexiguran ziclumeran (nex-z).\nThis setback for Intellia’s lead in vivo CRISPR program sharply elevates its regulatory and development risk profile, particularly given the company’s reliance on a...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-is-up-207-after-fda-halts-magnitu","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/intellia-therapeutics-ntla-is-up-207-after-fda-halts-magnitu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4588","LU1861559042.SGD","BK4207","NTLA","ATTR","BK4556","BK4535","BK4139","CM","LU1861558580.USD","BK4585"],"gpt_icon":0},{"id":"2602237009","title":"Bayer’s New Phase 4 ATTR-CM Study Tests Switching From Tafamidis to Acoramidis","url":"https://stock-news.laohu8.com/highlight/detail?id=2602237009","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602237009?lang=en_us&edition=fundamental","pubTime":"2026-01-10 00:33","pubTimestamp":1767976395,"startTime":"0","endTime":"0","summary":"Bayer AG ($BAYRY) announced an update on their ongoing clinical study. Bayer Explores Switch to New ATTR-CM Therapy in Phase 4 Study The study, off...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/bayers-new-phase-4-attr-cm-study-tests-switching-from-tafamidis-to-acoramidis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/bayers-new-phase-4-attr-cm-study-tests-switching-from-tafamidis-to-acoramidis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","LU1093756168.USD","BK4116","CM","ATTR","SWCH","BK4513","LU1093756325.SGD"],"gpt_icon":0}],"pageSize":4,"totalPage":3,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ATTR\",params:#limit:6,delay:false,,,undefined,":[]}}